Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanobiotix ( (NBTX) ) has provided an announcement.
On October 31, 2025, Nanobiotix announced a strategic royalty monetization agreement with HealthCare Royalty, securing up to $71 million in non-dilutive funding. This agreement is expected to extend the company’s cash runway into early 2028, supporting the development of its nanotherapeutic platforms and advancing key milestones in head and neck and lung cancer treatments. The deal involves HealthCare Royalty receiving a capped portion of milestones and royalties from sales of JNJ-1900 (NBTXR3), a novel oncology product. This financing aims to establish a financial foundation for Nanobiotix’s long-term growth and self-sustainability, reflecting confidence in its innovative cancer treatment approach.
The most recent analyst rating on (NBTX) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The overall stock score is primarily influenced by the company’s poor financial performance, which poses significant risks to its long-term viability. While there is some positive short-term technical momentum, the negative valuation metrics further weigh down the score. Strategic improvements are necessary for a more favorable outlook.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, with a focus on pioneering physics-based therapeutic approaches to enhance treatment outcomes for cancer and other major diseases. The company is listed on Euronext Paris and Nasdaq, and it owns over 25 patents related to nanotechnology platforms in oncology, bioavailability, biodistribution, and central nervous system disorders.
Average Trading Volume: 80,762
Technical Sentiment Signal: Buy
Current Market Cap: $906.9M
For an in-depth examination of NBTX stock, go to TipRanks’ Overview page.